Back to search

Belgium· BE-AMP-SAM475742-00

Gliclazide Lupin 60 mg

A gliclazide product containing gliclazide, registered in Belgium by Lupin (Europe). The same ATC class is registered in 14 of our 19 countries.

ATC A10BB09

Checked against FAMHP / AFMPS (Belgium) on

Informational only — not a medical device.

SOURCE REGISTER · BEFAMHP / AFMPS (Belgium)normalisedGliclazide Lupin 60 mgATCA10BB09REGISTER NO.BE-AMP-SAM475742-00PACKS LISTED0CHECKEDSeptember 26, 2026

Where it is registered

Gliclazide is registered in 14 of 19 countries.

Countries holding a registration under ATC A10BB09 (gliclazide), each read from that country’s own register.

  • This record: Belgium, from FAMHP / AFMPS (Belgium)
  • 7 of them publish a price we can compare per daily dose

Gliclazide · ATC A10BB09

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Italyprice
  • Japan
  • Netherlands
  • Polandprice
  • Switzerlandprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of gliclazide costs, country by country.

Normalised to the WHO defined daily dose (60 mg), the median price runs from $0.11 in France to $0.61 in Switzerland — a ×5.5 gap.

  • 3 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Gliclazide · price per daily dose (60 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$0.61
  • IT Italy$0.26
  • FR France$0.11
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

FAMHP / AFMPS (Belgium)
Active substance
Gliclazide
Manufacturer
Lupin (Europe)
Country
Belgium (BE)
ATC code
A10BB09
ATC class
Gliclazide
Defined daily dose
60 mg, O
Reimbursed
Not published by this register
Source register
FAMHP / AFMPS (Belgium)
Last checked
September 26, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

5 interactions on record for gliclazide.

Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Gliclazide · interactions on record

5 records

5 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
Mechanism and what to do, in the interaction check
Interaction register. Grades as the source publishes them.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/f3c501ae-e576-4907-bbfa-5b067f5a714e
GET /v1/drugs/f3c501ae-e576-4907-bbfa-5b067f5a714e?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Prolonged-release tablet",
  "source": "afmps",
  "status": "REVOKED",
  "name_en": "Gliclazide Lupin 60 mg",
  "name_fr": "Gliclazide Lupin 60 mg",
  "name_nl": "Gliclazide Lupin 60 mg",
  "amp_code": "SAM475742-00",
  "strengths": [
    "60.0000"
  ],
  "pack_count": 6,
  "substances": [
    "Gliclazide"
  ],
  "medicine_type": "ALLOPATHIC",
  "atc_description": "Gliclazide",
  "authorisation_numbers": [
    "BE475742"
  ]
}

See everything about gliclazide.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.